Dublin: The Irish government and pharmaceutical industry are expressing deep concern over US President Donald Trump’s proposed plan to impose tariffs of up to 250% on imported pharmaceutical products—measures that experts warn could devastate Ireland’s economy.
Although no official policy has been implemented yet, Trump’s remarks have already unsettled both Irish and EU officials, who fear that such a move could spark a transatlantic trade conflict. The pharmaceutical sector, a cornerstone of Ireland’s economy, is particularly vulnerable.
Massive Economic Risks for Ireland
Pharmaceuticals account for over half of Ireland’s total exports, with the United States serving as the country’s largest non-EU trading partner. Ireland is home to major global pharmaceutical manufacturers, including Pfizer, Johnson & Johnson, and AbbVie, whose exports to the US represent tens of billions of euros annually.
If Trump’s proposed tariff plan—beginning with a modest rate, then rising to 150% and ultimately 250% within a year—were to take effect, it would significantly increase the cost of Irish-made medicines in the US. This would erode their competitiveness, disrupt trade flows, and jeopardise thousands of jobs in key pharmaceutical hubs such as Cork, Limerick, and Dublin.
The economic impact would go far beyond pharmaceutical manufacturing. A downturn in the sector would lead to reduced corporate tax revenues, loss of foreign investment, and strain on local economies. The potential job losses are particularly concerning, as a significant proportion of the workforce includes Indian nationals employed in Ireland’s thriving life sciences industry.
Trump has frequently criticised Ireland and China as the United States’ chief competitors in the pharmaceutical industry. His new tariff plan is intended to repatriate pharmaceutical manufacturing to the US, citing economic nationalism as the motivation behind the escalating rates.
Irish PM: “Tariffs Will Hurt the US, Not Just Ireland”
Irish Prime Minister Micheál Martin has publicly condemned the tariff proposal, warning that it will hurt not only Ireland but also US pharmaceutical companies operating in the country. He noted that Trump’s own statements acknowledged a temporary exemption or delay for the pharmaceutical sector—initially subject to a 15% tariff for one to one-and-a-half years—but that this relief is short-lived under the current plan.
“Tariffs are damaging—not just to global trade, but to workers, consumers, and economies alike,” Martin said. “Many of the pharmaceutical companies operating here are American-owned. These companies have grown stronger because of their presence in Ireland and their ability to serve not just Europe but Asia as well.”
Martin also confirmed that he had spoken with European Commission President Ursula von der Leyen and Commission Vice-President Maroš Šefčovič to discuss coordinated responses and protect Ireland’s economic interests.
Irish Samachar English News
{OR} Kindly click to follow the Irish Samachar News channel on WhatsApp